Peter Gibbs

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7862333/publications.pdf

Version: 2024-02-01

147 papers	4,547 citations	257450 24 h-index	106344 65 g-index
149 all docs	149 docs citations	149 times ranked	7564 citing authors

#	Article	IF	Citations
1	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science Translational Medicine, 2016, 8, 346ra92.	12.4	1,036
2	Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. New England Journal of Medicine, 2018, 379, 1519-1528.	27.0	591
3	Effect of Aspirin on Disability-free Survival in the Healthy Elderly. New England Journal of Medicine, 2018, 379, 1499-1508.	27.0	392
4	Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. New England Journal of Medicine, 2022, 386, 2261-2272.	27.0	337
5	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncology, The, 2017, 18, 1159-1171.	10.7	293
6	SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2016, 34, 1723-1731.	1.6	289
7	Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.. Journal of Clinical Oncology, 2020, 38, LBA4-LBA4.	1.6	150
8	The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. Acta OncolÃ³gica, 2018, 57, 1438-1444.	1.8	78
9	Impact of clinical and molecular features on risk of recurrence following curative intent resection of metastases in metastatic colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 785-785.	1.6	67
10	Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. The Lancet Gastroenterology and Hepatology, 2018, 3, 635-643.	8.1	60
11	Blood-Based Protein Biomarker Panel for the Detection of Colorectal Cancer. PLoS ONE, 2015, 10, e0120425.	2.5	59
12	An inverse stageâ€shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVIDâ€19 pandemic. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 359-367.	1.1	59
13	Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. BMC Cancer, 2014, 14, 897.	2.6	54
14	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. Clinical Colorectal Cancer, 2018, 17, e617-e629.	2.3	54
15	Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. Gut, 2019, 68, 465-474.	12.1	52
16	A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer, 2002, 94, 470-476.	4.1	50
17	Functional Screening Identifies miRNAs Influencing Apoptosis and Proliferation in Colorectal Cancer. PLoS ONE, 2014, 9, e96767.	2.5	49
18	Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial. Cancer Chemotherapy and Pharmacology, 2011, 67, 153-163.	2.3	45

#	Article	IF	Citations
19	Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, e9-e15.	2.3	45
20	Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer. Clinical Cancer Research, 2018, 24, 5602-5609.	7.0	45
21	Targeted therapy for metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2018, 18, 991-1006.	2.4	44
22	Primary Tumor Resection in Patients With Metastatic Colorectal Cancer Is Associated With Reversal of Systemic Inflammation and Improved Survival. Clinical Colorectal Cancer, 2015, 14, 185-191.	2.3	42
23	Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. Journal of Gastrointestinal Oncology, 2017, 8, 1079-1099.	1.4	34
24	Impact of diabetes on clinicopathologic and genetic features of colorectal cancer formation.. Journal of Clinical Oncology, 2013, 31, 426-426.	1.6	28
25	Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repairâ€“Proficient Stage II Colon Cancer. Clinical Cancer Research, 2016, 22, 3488-3498.	7.0	26
26	A Pilot Human Evaluation of a Formulation of Irinotecan and Hyaluronic Acid in 5-Fluorouracil-Refractory Metastatic Colorectal Cancer Patients. Chemotherapy, 2009, 55, 49-59.	1.6	25
27	The rapidly escalating cost of treating colorectal cancer in <scp>A</scp>ustralia. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 33-40.	1.1	24
28	Multidisciplinary Management of Locally Advanced Rectal Cancerâ€”An Evolving Landscape?. Clinical Colorectal Cancer, 2015, 14, 251-261.	2.3	21
29	Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer. JMIR Research Protocols, 2017, 6, e43.	1.0	21
30	Patterns of care and outcomes for elderly patients with metastatic colorectal cancer in Australia. Journal of Geriatric Oncology, 2015, 6, 387-394.	1.0	20
31	Recurrence in patients with stage I colorectal cancer. ANZ Journal of Surgery, 2016, 86, 49-53.	0.7	20
32	Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. Clinical Colorectal Cancer, 2017, 16, e73-e88.	2.3	19
33	An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastinâ„¢) [ASCENT]. BMC Cancer, 2013, 13, 120.	2.6	18
34	Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma. BMC Cancer, 2015, 15, 802.	2.6	17
35	The Genes and Genetics of Malignant Melanoma. Journal of Cutaneous Medicine and Surgery, 2002, 6, 229-235.	1.2	15
36	Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer. Journal of Medical Economics, 2017, 20, 193-199.	2.1	15

#	Article	IF	Citations
37	Lymph node yield following colorectal cancer surgery. ANZ Journal of Surgery, 2011, 81, 266-271.	0.7	14
38	Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients. Journal of Cancer Epidemiology, 2015, 2015, 1-8.	1.1	13
39	Patterns of care for metastatic renal cell carcinoma in Australia. BJU International, 2015, 116, 36-41.	2.5	12
40	Sequencing Circulating Cell-Free DNA: The Potential to Refine Precision Cancer Medicine. Clinical Chemistry, 2016, 62, 796-798.	3.2	12
41	Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. Seminars in Cancer Biology, 2018, 52, 241-252.	9.6	12
42	Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?. Internal Medicine Journal, 2019, 49, 446-454.	0.8	12
43	The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. PLoS ONE, 2020, 15, e0229900.	2.5	12
44	Serial circulating tumor DNA (ctDNA) and recurrence risk in patients (pts) with resectable colorectal liver metastasis (CLM).. Journal of Clinical Oncology, 2016, 34, e15131-e15131.	1.6	12
45	The Genes and Genetics of Malignant Melanoma. Journal of Cutaneous Medicine and Surgery, 2002, 6, 229-235.	1.2	11
46	Quality of life in the FOXFIRE, SIRFLOX and FOXFIREâ€global randomised trials of selective internal radiotherapy for metastatic colorectal cancer. International Journal of Cancer, 2020, 147, 1078-1085.	5.1	11
47	Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. Current Problems in Cancer, 2021, 45, 100637.	2.0	11
48	REsect: Blinded assessment of amenability to potentially curative treatment of previously unresectable colorectal cancer liver metastases (CRC LM) after chemotherapy Â± RadioEmbolization (SIRT) in the randomized SIRFLOX trial.. Journal of Clinical Oncology, 2017, 35, 3532-3532.	1.6	11
49	Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review. Pharmacoeconomics, 2020, 38, 683-713.	3.3	10
50	Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma. Clinical Colorectal Cancer, 2017, 16, e45-e54.	2.3	9
51	Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer. Modern Pathology, 2020, 33, 483-495.	5.5	9
52	Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer.. Journal of Clinical Oncology, 2017, 35, 4101-4101.	1.6	9
53	Primary Tumor Resection and Overall Survival in Patients With Metastatic Colorectal Cancer Treated With Palliative Intent. Clinical Colorectal Cancer, 2016, 15, e125-e132.	2.3	8
54	Cancer history and risk factors in healthy older people enrolling in the ASPREE clinical trial. Contemporary Clinical Trials, 2020, 96, 106095.	1.8	8

#	Article	IF	Citations
55	CD8⁺ tumorâ€infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival. Clinical and Translational Immunology, 2020, 9, e1155.	3.8	8
56	The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 314-321.	1.1	7
57	A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease. Cancers, 2021, 13, 5815.	3.7	7
58	Previous Bevacizumab and Efficacy of Later Antiâ€"Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry. Clinical Colorectal Cancer, 2018, 17, e593-e599.	2.3	6
59	Genomic Risk Prediction for Breast Cancer in Older Women. Cancers, 2021, 13, 3533.	3.7	6
60	Circulating tumor DNA (ctDNA) in nonmetastatic colorectal cancer (CRC): Potential role as a screening tool.. Journal of Clinical Oncology, 2015, 33, 518-518.	1.6	6
61	The outcome of patients (pts) with metastatic colorectal cancer (mCRC) based on site of metastases (mets) and the impact of molecular markers and site of primary cancer on metastatic pattern.. Journal of Clinical Oncology, 2017, 35, 3560-3560.	1.6	6
62	Phase II APEC trial: The impact of primary tumor side on outcomes of firstâ€line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wildâ€type metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 225-230.	1.1	5
63	Tumor burden (TB) as a prognostic indicator in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 572-572.	1.6	5
64	The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers.. Journal of Clinical Oncology, 2016, 34, 3511-3511.	1.6	5
65	A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC).. Journal of Clinical Oncology, 2019, 37, 3518-3518.	1.6	5
66	Risk-Adjusted Pathologic Margin Positivity Rate: A Problematic Quality Indicator. Journal of Clinical Oncology, 2015, 33, 1410-1411.	1.6	4
67	Drinking from the firehose â€" A clinician's perspective on the challenges of delivering biomarker-driven care in routine practice. European Journal of Cancer, 2021, 157, 301-305.	2.8	4
68	Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).. Journal of Clinical Oncology, 2013, 31, LBA445-LBA445.	1.6	4
69	Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, e16206-e16206.	1.6	4
70	Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. Pharmacoeconomics, 2020, 38, 1263-1275.	3.3	3
71	The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab.. Journal of Clinical Oncology, 2018, 36, 719-719.	1.6	3
72	Effect of Aspirin on Melanoma Incidence in Older Persons: Extended Follow-up of a Large Randomized Double-blind Placebo-controlled Trial. Cancer Prevention Research, 2022, 15, 365-375.	1.5	3

#	Article	IF	Citations
73	Is increasing nodal count associated with improved recurrenceâ€free and overall survival following standard right hemicolectomy for colon cancer?. Journal of Surgical Oncology, 2022, 126, 523-534.	1.7	3
74	Tâ€stage downstaging of locally advanced rectal cancer after neoadjuvant chemoradiotherapy is not associated with reduced recurrence after adjusting for tumour characteristics. Journal of Surgical Oncology, 2022, 126, 728-739.	1.7	3
75	The American Brachytherapy Society consensus statement for permanent implant brachytherapy using Yttrium-90 microsphere radioembolization for liver tumors. Brachytherapy, 2022, 21, 569-591.	0.5	3
76	Evidence supports adjuvant radiotherapy in selected patients with rectal cancer. ANZ Journal of Surgery, 2004, 74, 152-157.	0.7	2
77	RE: Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer. Journal of the National Cancer Institute, 2015, 107, djv149-djv149.	6.3	2
78	Adequate SIRT activity dose is as important as adequate chemotherapy dose â€“ Authors' reply. Lancet Oncology, The, 2017, 18, e637.	10.7	2
79	Incidence of pulmonary embolism in patients with newly diagnosed colorectal cancer. ANZ Journal of Surgery, 2018, 88, E228-E231.	0.7	2
80	Precision oncology using a clinicianâ€directed, tailored approach to molecular profiling. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 84-90.	1.1	2
81	Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group. Clinical Colorectal Cancer, 2021, 20, 245-255.	2.3	2
82	Investigating real-world treatment sequencing outcomes in advanced pancreatic cancer: A purple translational registry analysis.. Journal of Clinical Oncology, 2021, 39, 386-386.	1.6	2
83	BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17.. Journal of Clinical Oncology, 2012, 30, 3515-3515.	1.6	2
84	The tumor immune microenvironment differs between metastatic castrate resistant prostate cancer (CRPC) and hormone sensitive prostate cancer (HSPC).. Journal of Clinical Oncology, 2019, 37, 251-251.	1.6	2
85	Real-world survival outcomes of using neoadjuvant chemotherapy in pancreatic cancer patients: Findings from the PURPLE clinical registry.. Journal of Clinical Oncology, 2020, 38, e16755-e16755.	1.6	2
86	Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+/HR+ metastatic breast cancer.. Journal of Clinical Oncology, 2020, 38, 1038-1038.	1.6	2
87	Realâ€world staging computed tomography scanning technique and important reporting discrepancies in pancreatic ductal adenocarcinoma. ANZ Journal of Surgery, 2022, 92, 1789-1796.	0.7	2
88	An incorrect diagnosis of metastatic colorectal cancer: The need for tissue diagnosis prior to treatment. Asia-Pacific Journal of Clinical Oncology, 2007, 3, 106-107.	1.1	1
89	Radioembolization for colorectal cancer liver metastases: current role and future opportunities â€“ the medical oncologistâ€™s perspective. Colorectal Cancer, 2014, 3, 345-362.	0.8	1
90	Problematic Use of Multiple Subgroup Analyses in Assessing the Impact of Aspirin in Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 2226-2226.	1.6	1

#	Article	IF	Citations
91	Initial experience of TAS-102 chemotherapy in Australian patients with chemorefractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2021, 39, 71-71.	1.6	1
92	Treatment and Outcomes of Oligometastatic Colorectal Cancer Limited to Lymph Node Metastases. Clinical Colorectal Cancer, 2021, , .	2.3	1
93	Prescribing patterns for bevacizumab in first-line metastatic colorectal cancer: Exploring the introduction of a new drug into routine clinical practice.. Journal of Clinical Oncology, 2012, 30, 665-665.	1.6	1
94	Patterns of care according to treatment intent for metastatic colorectal cancer (mCRC): A two-year review of routine practice.. Journal of Clinical Oncology, 2012, 30, 682-682.	1.6	1
95	Patterns of care of elderly patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, e14640-e14640.	1.6	1
96	Can systemic inflammation at diagnosis predict benefit from primary resection in metastatic colorectal cancer (mCRC)?. Journal of Clinical Oncology, 2013, 31, 410-410.	1.6	1
97	Impact of tumor site on bevacizumab (BEV) efficacy in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, e14558-e14558.	1.6	1
98	Safety and efficacy of bevacizumab and systemic therapy in metastatic colorectal cancer (mCRC) patients with peritoneal disease in the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) database.. Journal of Clinical Oncology, 2014, 32, 569-569.	1.6	1
99	Left versus right sided colorectal cancer: Teasing out drivers of disparity in outcomes in metastatic disease.. Journal of Clinical Oncology, 2017, 35, 682-682.	1.6	1
100	Treatment sequencing and outcomes in synchronous metastatic rectal cancer.. Journal of Clinical Oncology, 2017, 35, 750-750.	1.6	1
101	Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. Journal of Clinical Oncology, 2018, 36, 3534-3534.	1.6	1
102	Impact of primary tumor side (TS) on outcomes of once-every-2-weeks (q2w) cetuximab + first-line (1L) FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. Journal of Clinical Oncology, 2018, 36, 747-747.	1.6	1
103	Metastasectomy and BRAF mutation: An analysis of survival outcome in metastatic colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 3531-3531.	1.6	1
104	Left- versus right-side metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival.. Journal of Clinical Oncology, 2019, 37, 623-623.	1.6	1
105	Metastatic colorectal cancer and management in public versus private hospitals: Similarities and differences.. Journal of Clinical Oncology, 2013, 31, 497-497.	1.6	1
106	Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).. Journal of Clinical Oncology, 2013, 31, 3575-3575.	1.6	1
107	Regular aspirin (ASA) use and survival in patients with PIK3CA-mutated metastatic colorectal cancer (CRC).. Journal of Clinical Oncology, 2014, 32, 386-386.	1.6	1
108	Delivery and effectiveness of adjuvant therapy for stage III colon cancer in routine clinical practice.. Journal of Clinical Oncology, 2014, 32, e14540-e14540.	1.6	1

#	Article	IF	Citations
109	Survival, mortality and morbidity outcomes after oesophagogastric cancer surgery in New South Wales, 2001â€“2008. Medical Journal of Australia, 2014, 201, 447-447.	1.7	1
110	Immune profile and survival outcomes in stage 2 colon cancer.. Journal of Clinical Oncology, 2016, 34, 3576-3576.	1.6	1
111	Biology and Clinical Implications of Fecal Occult Blood Test Screen-Detected Colorectal Cancer. JNCI Cancer Spectrum, 2022, 6, .	2.9	1
112	Incident Cancer Risk and Signatures Among Older MUTYH Carriers: Analysis of Population-Based and Genomic Cohorts. Cancer Prevention Research, 2022, 15, 509-519.	1.5	1
113	Role of radiotherapy in solitary bone plasmacytomas. Asia-Pacific Journal of Clinical Oncology, 2005, 1, 35-40.	1.1	0
114	Anticoagulation prophylaxis for central venous catheter-associated thrombosis in cancer patients: An Australian perspective. Asia-Pacific Journal of Clinical Oncology, 2008, 4, 2-5.	1.1	0
115	Radioembolization for hepatocellular carcinoma: current role and future directions â€“ the medical oncologist's perspective. Hepatic Oncology, 2015, 2, 117-132.	4.2	0
116	Insights into the SIRFLOX study. Hepatic Oncology, 2016, 3, 191-192.	4.2	0
117	Reply to E.C. Harrold et al and A.O. Ayoola et al. Journal of Clinical Oncology, 2016, 34, 4194-4195.	1.6	0
118	Australian contemporary management of synchronous metastatic colorectal cancer. ANZ Journal of Surgery, 2018, 88, 71-76.	0.7	0
119	How accurate are medical oncologistsâ€™ impressions of management of metastatic colorectal cancer in Australia?. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e167-e174.	1.1	0
120	Second primary cancers in patients with sporadic deficient mismatch repair (dMMR) colorectal cancer (CRC).. Journal of Clinical Oncology, 2021, 39, 45-45.	1.6	0
121	Variable implementation of optimal therapeutic strategies in metastatic colorectal cancer: Reviewing rates of liver resection and triplet chemotherapy across Australian hospitals as potential quality indicators.. Journal of Clinical Oncology, 2021, 39, 248-248.	1.6	0
122	Patterns of care according to treatment intent for metastatic colorectal cancer (mCRC): A 2.5-year review of routine practice.. Journal of Clinical Oncology, 2012, 30, e16516-e16516.	1.6	0
123	Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status?. Journal of Clinical Oncology, 2013, 31, 534-534.	1.6	0
124	First-line clinical trials and metastatic colorectal cancer: How selected are clinical trial participants?. Journal of Clinical Oncology, 2013, 31, 524-524.	1.6	0
125	Understanding why some people with stage III colon cancer do not receive adjuvant chemotherapy.. Journal of Clinical Oncology, 2013, 31, e14608-e14608.	1.6	0
126	Primary tumor resection in metastatic colorectal cancer (mCRC): A prospective cohort study.. Journal of Clinical Oncology, 2013, 31, 3584-3584.	1.6	0

#	Article	IF	Citations
127	Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status?. Journal of Clinical Oncology, 2013, 31, e14583-e14583.	1.6	0
128	Resection of colorectal cancer (CRC) metastases in routine practice.. Journal of Clinical Oncology, 2014, 32, 599-599.	1.6	0
129	Point-of-care capture of clinical interventions for metastatic colorectal cancer (mCRC) to develop and validate novel markers of the quality of cancer care.. Journal of Clinical Oncology, 2014, 32, e17637-e17637.	1.6	0
130	Prognostic impact of clinicopathologic features in metastatic rectal versus colon cancer.. Journal of Clinical Oncology, 2014, 32, e14518-e14518.	1.6	0
131	Effect of DNA-PK dependent phosphorylation of topo-I-S10 on its rate of proteasomal degradation and CPT response.. Journal of Clinical Oncology, 2015, 33, 606-606.	1.6	0
132	Survival impact of adjuvant chemotherapy for resected early-stage rectal adenocarcinoma.. Journal of Clinical Oncology, 2015, 33, 712-712.	1.6	0
133	Can neutrophil-to-lymphocyte ratio be used to identify patients with metastatic renal cell carcinoma who may gain greater benefit from cytoreductive nephrectomy?. Journal of Clinical Oncology, 2015, 33, 490-490.	1.6	0
134	SIRFLOX study: Novel approach to define depth of response (DpR) within a volumetric model in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 3542-3542.	1.6	0
135	Hypertension and beta-blocker use as prognostic and predictive factors in metastatic colorectal cancer: A retrospective analysis of NCIC CTG CO.17.. Journal of Clinical Oncology, 2016, 34, e15025-e15025.	1.6	0
136	Examining progression-free survival in first- and second-line treatment for BRAF-mutant metastatic colorectal cancer (CRC).. Journal of Clinical Oncology, 2017, 35, 728-728.	1.6	0
137	A real-world registry to evaluate HER2-directed therapy in Australian patients with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2017, 35, e12515-e12515.	1.6	0
138	Which side is better? The impact of primary tumor side in early stage colorectal cancer (CRC).. Journal of Clinical Oncology, 2017, 35, e15106-e15106.	1.6	0
139	Stage-based variation in the impact of colon cancer surveillance.. Journal of Clinical Oncology, 2019, 37, 3609-3609.	1.6	0
140	Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease.. Journal of Clinical Oncology, 2020, 38, 78-78.	1.6	0
141	Real-world outcomes for neoadjuvant capecitabine versus infusional 5-fluorouracil in the treatment of locally advanced rectal cancer.. Journal of Clinical Oncology, 2020, 38, e16124-e16124.	1.6	0
142	Do assumptions in health economic evaluations hamper drug uptake?. Journal of Clinical Oncology, 2020, 38, e19289-e19289.	1.6	0
143	Comment on Timing of Surgery For Patients With Rectal Cancers Not Responding to Preoperative Chemoradiation. JAMA Surgery, 2022, , .	4.3	0
144	Exploring Survival Outcomes in Metastatic Colorectal Cancer Harboring KRAS A146 Mutations: Important Distinction or Simple Distraction?. JCO Precision Oncology, 2022, 6, e2100564.	3.0	0

#	Article	IF	Citations
145	Association between hypertension and cutaneous melanoma, and the effect of aspirin: extended follow-up of a large randomised controlled trial. Cancer Epidemiology, 2022, 79, 102173.	1.9	0
146	Cancer diagnosis, cancer treatment, and association with cardiovascular disease in older adults: Results from ASPREE.. Journal of Clinical Oncology, 2022, 40, 12086-12086.	1.6	0
147	FORECAST-1: Feasibility of organoid response assessment to define effective treatments for patients with colorectal cancer after failure of standard therapy.. Journal of Clinical Oncology, 2022, 40, 3583-3583.	1.6	0